Analysts at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT - Get Free Report) in a report issued on Wednesday. The firm set a "hold" rating on the stock.
Separately, JMP Securities reissued a "market outperform" rating and set a $10.00 target price on shares of DBV Technologies in a report on Friday, January 10th.
Get Our Latest Research Report on DBVT
DBV Technologies Stock Performance
Shares of DBV Technologies stock traded up $0.64 during midday trading on Wednesday, hitting $9.17. 92,375 shares of the company traded hands, compared to its average volume of 183,505. DBV Technologies has a 12 month low of $2.20 and a 12 month high of $9.89. The stock has a market cap of $251.17 million, a price-to-earnings ratio of -2.04 and a beta of -0.08. The firm's fifty day moving average price is $6.01 and its 200-day moving average price is $4.52.
DBV Technologies (NASDAQ:DBVT - Get Free Report) last posted its earnings results on Friday, April 11th. The company reported ($1.10) earnings per share for the quarter. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. The business had revenue of $0.51 million for the quarter. Equities research analysts forecast that DBV Technologies will post -7.05 earnings per share for the current year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC purchased a new position in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent filing with the Securities and Exchange Commission. 71.74% of the stock is currently owned by hedge funds and other institutional investors.
DBV Technologies Company Profile
(
Get Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
See Also
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
